Cerity Partners
CRL icon

Cerity Partners’s Charles River Laboratories CRL Stock Holding History

Cerity Partners’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$705K Sell
4,085
-2,163
-35% -$401K ﹤0.01% 2075
2025
Q4 		$1.25M Buy
6,248
+1,623
+35% +$294K ﹤0.01% 1601
2025
Q3 		$724K Buy
+4,625
New +$735K ﹤0.01% 1758
2025
Q1 		– Sell
-3,615
Closed -$710K – 2507
2024
Q4 		$710K Sell
3,615
-1,276
-26% -$246K ﹤0.01% 1576
2024
Q3 		$963K Buy
4,891
+1,943
+66% +$404K ﹤0.01% 1409
2024
Q2 		$609K Sell
2,948
-4,151
-58% -$941K ﹤0.01% 1456
2024
Q1 		$1.92M Buy
7,099
+5,629
+383% +$1.34M 0.01% 989
2023
Q4 		$348K Buy
+1,470
New +$289K ﹤0.01% 1443
2023
Q2 		– Sell
-1,198
Closed -$242K – 1706
2023
Q1 		$242K Sell
1,198
-1,239
-51% -$281K ﹤0.01% 1638
2022
Q4 		$531K Buy
2,437
+458
+23% +$100K ﹤0.01% 922
2022
Q3 		$389K Sell
1,979
-9,083
-82% -$1.96M ﹤0.01% 800
2022
Q2 		$2.37M Sell
11,062
-11,646
-51% -$2.85M 0.03% 374
2022
Q1 		$6.45M Buy
+22,708
New +$7M 0.1% 167

Other funds holding CRL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Cerity Partners's CRL Position: Q1 2026 in Review

Cerity Partners reduced its Charles River Laboratories (CRL) stake by 35% in Q1 2026, selling an estimated $401K and leaving 4,085 shares worth $705K. The position accounts for ﹤0.01% of the portfolio, ranked #2075.

Cerity Partners first reported a position in CRL in Q1 2022 and has held it in 13 quarters since. The position peaked at $6.45M in Q1 2022. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Cerity Partners held 4,085 shares of Charles River Laboratories worth $705K as of Q1 2026.
  • Cerity Partners sold 2,163 Charles River Laboratories shares in Q1 2026, an estimated $401K.
  • Charles River Laboratories made up ﹤0.01% of Cerity Partners's portfolio in Q1 2026, its #2075 holding.
  • Cerity Partners first reported a position in Charles River Laboratories in Q1 2022 and has held it in 13 quarters since.
  • Cerity Partners's Charles River Laboratories position peaked at $6.45M in Q1 2022.
  • 557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Cerity Partners's 13F filing for Q1 2026, filed 15 May 2026.